` SNY (Sanofi SA) vs S&P 500 Comparison - Alpha Spread

SNY
vs
S&P 500

Over the past 12 months, SNY has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +14% growth.

Stocks Performance
SNY vs S&P 500

Loading
SNY
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
SNY vs S&P 500

Loading
SNY
S&P 500
Difference
www.alphaspread.com

Performance By Year
SNY vs S&P 500

Loading
SNY
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Sanofi SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Sanofi SA
Glance View

Sanofi SA, a titan in the global healthcare sector, operates at the intricate crossroads of pharmaceutical innovation and patient care, driven by an unyielding commitment to improving human health. Emerging from its French roots, Sanofi has strategically positioned itself as a global leader in pharmaceuticals, vaccines, and consumer healthcare. The company’s success is essentially anchored in its capacity to consistently develop and commercialize life-saving drugs that address a myriad of health concerns, ranging from diabetes and cardiovascular diseases to rare disorders and oncology. Underlining its robust revenue engine is Sanofi's extensive R&D infrastructure that fuels its pipeline with groundbreaking therapies, reflecting a dynamic blend of scientific acumen and market-focused agility. By leveraging a hybrid model that integrates cutting-edge research with strategic alliances and acquisitions, Sanofi ensures a sustained presence in the highly competitive biopharmaceutical landscape. Enabling this network of innovation and impact is Sanofi's diverse portfolio, a balanced mix of specialty and established prescription drugs, over-the-counter products, and the critical arm of vaccines led by its Sanofi Pasteur division. This diversification offers both growth opportunities and stability, cushioning against the volatile tides of patent expirations and regulatory changes. Its vaccines segment, in particular, is a cornerstone in Sanofi's business, capturing substantial market share with products critical to global immunization efforts, further amplified by its role in responding to health emergencies like the COVID-19 pandemic. With a geographically expansive sales footprint and strategic marketing strategies, Sanofi capitalizes on emerging market opportunities while maintaining a strong presence in established regions, effectively making its bottom line a testimony to its operational excellence and strategic foresight in harmonizing science with humanity.

SNY Intrinsic Value
92.43 USD
Undervaluation 48%
Intrinsic Value
Price
Back to Top